{
GSK plc

Companies

}
AstraZeneca shares drop amid Chinese investigation into sales practices
AstraZeneca's shares fell 8.4% on the London Stock Exchange amid concerns over a Chinese investigation into alleged aggressive sales tactics for its oncology drugs, Tagrisso and Imjudo. The company's local president, Leon Wang, is under investigation, signaling increased scrutiny from Beijing. Despite the turmoil, AstraZeneca aims for $80 billion in sales by 2030, up from $45.8 billion in 2023, with plans to launch 20 new drugs by the decade's end.
Il Sole 24 ORE
United States Dollar AstraZeneca PLC GSK plc GBR CHN Gsk Leon Wang
Regulatory & Legal, Market Report
19:58 05.11.2024
financial crisis at 23andme raises concerns over customer dna data security
23andMe faces potential bankruptcy, raising concerns over the fate of customer DNA data, particularly for Swiss users, where genetic data is generally well protected. Despite claims of data security, the company’s policies allow for data sale during acquisitions, and past breaches have compromised sensitive information. With a significant drop in value and management turmoil, the future of 23andMe and its handling of genetic data remains uncertain.
Tages-Anzeiger
United States Dollar Google Inc. 23andMe Holding Co. GSK plc CHE USA Larry Page Rupert Murdoch Sergey Brin Craig Venter Anne Wojcicki Show more
Finance & Economy, News Article
12:19 04.11.2024
ubs maintains neutral rating for gsk with target price of 1580 pence
UBS has maintained a 'Neutral' rating for GSK, setting a target price of 1580 pence. Analyst Jo Walton has slightly increased his 2025 estimates but expresses skepticism about the outlook for the Shingrix vaccine in China starting in 2026.
MarketScreener
British Pound Sterling UBS AG GSK plc GBR Jo Walton
TradFi, Market Report
12:42 31.10.2024
gsk vaccine sales decline amid lower demand for rsv and shingles shots
GSK's vaccine sales plummeted in the third quarter, with shingles vaccine sales down 7% and respiratory syncytial virus (RSV) shot Arexvy dropping 72% year over year. The decline is attributed to a narrower CDC recommendation, prioritization of COVID vaccinations, and lower RSV infection rates. GSK anticipates a low single-digit decline in overall vaccine sales for the year.
BioPharma Dive
British Pound Sterling Pfizer Inc. GSK plc GBR Luke Miels Donald Trump
Finance & Economy, Market Report
20:15 30.10.2024
gsk vaccine sales fall short of expectations impacting overall profit performance
GSK Plc reported a decline in sales for two of its major vaccines in the third quarter, attributed to access issues in the US. Arexvy, for respiratory syncytial virus, generated £188 million, falling short of the £290 million forecast, while Shingrix sales reached £739 million, below the expected £895 million.
bloomberg.com
United States Dollar British Pound Sterling GSK plc GBR Arexvy Shingrix
Finance & Economy, Market Report
08:18 30.10.2024
european markets set to decline ahead of growth data and earnings reports
European markets are set to open lower, influenced by the EU's decision to raise tariffs on Chinese electric vehicles, with stocks like Nio and Geely experiencing declines. The U.K. is poised to reveal its first budget in 14 years, while investors are eyeing potential impacts on various stocks. Additionally, analysts suggest that the dollar may weaken under a Trump presidency, despite initial expectations of a stronger currency.
CNBC
Euro UBS AG Volkswagen AG GSK plc GBR Erik Knutzen Mio Kato Rachel Reeves Lisa Kailai Han Dylan Butts Show more
Finance & Economy, Market Report
06:43 30.10.2024
gsk partners with chimagen for lupus drug deal worth up to 850 million
GSK Plc has acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for up to $850 million, enhancing its lupus treatment pipeline. The deal includes a $300 million upfront payment, with Chimagen eligible for up to $550 million in success-based milestones. The antibody drug, currently in early clinical trials for leukemia and lymphoma, is set to enter early trials for lupus in 2025.
bloomberg.com
United States Dollar Chimagen Biosciences GSK plc CHN
Healthcare, Press Release
13:00 29.10.2024
lyell immunopharma acquires immPact bio to refocus on cancer therapies
Lyell Immunopharma is acquiring cell therapy startup ImmPact Bio for $30 million in cash and 37.5 million shares, with potential additional shares based on milestones. The company is streamlining its research focus on differentiated cellular immunotherapies for cancer, including the promising IMPT-314 therapy for blood cancers, while halting less successful projects. Following challenges since its IPO, Lyell aims for a turnaround with a financial runway extending into 2027.
BioPharma Dive
United States Dollar Bristol-Myers Squibb Company GSK plc USA Lynn Seely Juno Therapeutics
Healthcare, News Article
23:54 24.10.2024
cdc recommends lowering pneumococcal vaccine age boosting market potential
The CDC's advisory panel has recommended lowering the routine pneumococcal vaccination age from 65 to 50, potentially expanding the market for vaccines like Merck's Capvaxive and Pfizer's Prevnar. Analysts have adjusted sales forecasts, anticipating significant revenue growth for these vaccines, particularly for Merck in the near term, though competition from Vaxcyte's candidate may emerge by 2028.
BioPharma Dive
United States Dollar Pfizer Inc. Vaxcyte, Inc. GSK plc Merck & Co., Inc. USA Daina Graybosch Roger Song Akash Tewari Show more
Healthcare, Market Report
18:16 24.10.2024
FDA expands Pfizer RSV vaccine approval to younger adults at risk
The FDA has expanded the approval of Pfizer’s RSV vaccine, Abrysvo, to include adults aged 18 to 59 years at increased risk of respiratory syncytial virus, in addition to those aged 60 and older and pregnant women. Despite three available vaccines, uptake remains slow, partly due to CDC recommendations focusing on higher-risk individuals over 75. GSK has also received expanded approval for its RSV vaccine, Arexvy, for adults aged 50 to 59.
BioPharma Dive
United States Dollar Moderna, Inc. GSK plc Pfizer Inc. USA Joe Biden Michael Yee Show more
Healthcare, News Article
17:47 23.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Corporate Responsibility & ESG Market Sentiment Analysis Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Banking Regulations Tokenomics and Crypto Economics Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD Credit Suisse Real Estate Fund Siat NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Karin Keller-Sutter Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Ueli Maurer Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.